FGAM
TGTX icon

Financial Gravity Asset Management’s TG Therapeutics TGTX Stock Holding History

Financial Gravity Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5
Closed -$80 – 1756
2024
Q1 		$80 Buy
5
+2
+67% +$32 ﹤0.01% 987
2023
Q4 		$58 Buy
+3
New +$35 ﹤0.01% 1122
2019
Q4 		$11K Hold
41
– – 0.01% 1182
2019
Q3 		$0 Hold
41
– – ﹤0.01% 1545
2019
Q2 		$0 Hold
41
– – ﹤0.01% 1654
2019
Q1 		$0 Buy
+41
New +$222 ﹤0.01% 1540
2018
Q3 		$0 Buy
+41
New +$468 ﹤0.01% 1612

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Financial Gravity Asset Management's TGTX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 5 shares — an estimated $80 sold.

Financial Gravity Asset Management first reported a position in TGTX in Q3 2018 and held it in 7 quarters. The position peaked at $11K in Q4 2019. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 5 TG Therapeutics shares in Q2 2024, an estimated $80.
  • Financial Gravity Asset Management first reported a position in TG Therapeutics in Q3 2018 and held it in 7 quarters.
  • Financial Gravity Asset Management's TG Therapeutics position peaked at $11K in Q4 2019.
  • 259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.